Search

Your search keyword '"Schepis, F."' showing total 151 results

Search Constraints

Start Over You searched for: Author "Schepis, F." Remove constraint Author: "Schepis, F." Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
151 results on '"Schepis, F."'

Search Results

2. OC.11.1: UNDERDILATION STRATEGY FOR TIPS PLACEMENT REDUCES INCIDENCE OF OVERT HEPATIC ENCEPHALOPATHY WITHOUT AFFECTING CLINICAL EFFICACY AND SURVIVAL: RESULTS OF A MULTICENTER PROSPECTIVE ITALIAN STUDY

3. BOC.02.7: UNDERDILATED NEOADJUVANT-TIPS IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSION CANDIDATES TO OPERATIVE INTERVENTIONS

4. BOC.02.4: EPISODIC OVERT HEPATIC ENCEPHALOPATHY AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT DOES NOT INCREASE MORTALITY IN PATIENTS WITH CIRRHOSIS

5. OC.05.2: FIRST AND FURTHER LIVER DECOMPENSATION IN PATIENTS WITH METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE: WHAT CLINICAL IMPACT?

6. Angiopoietin-2 and the Vascular Endothelial Growth Factor Promote Migration and Invasion in Hepatocellular Carcinoma- and Intrahepatic Cholangiocarcinoma-Derived Spheroids

7. Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis

8. Response to “Hepatic encephalopathy and survival after transjugular intra-hepatic portosystemic shunt: do spontaneous portosystemic shunts matter?”

9. Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study

10. A machine learning enabled score based on large varices predicts 5- and 10-year hepatocellular carcinoma (HCC) development in a 12-year prospective cohort of patients with compensated advanced chronic liver disease

11. Serum procalcitonin predicts mortality independently of the presence of ACLF in patients with cirrhosis and ascites hospitalized for suspicious infection and treated with empiric antibiotic therapy

12. Presence and severity of esophageal varices drives portal hypertension-related complications in compensated advanced nonalcoholic fatty liver disease

13. TIPS under-dilation strategy with new controlled expansion endoprosthesis: A hemodynamic and imaging confirmation of its feasibility

14. Corrigendum to ‘Baveno VII – Renewing consensus in portal hypertension’ [J Hepatol (2022) 959-974, (S0168827821022996), (10.1016/j.jhep.2021.12.022)]

15. Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study

16. The impact of first and further decompensation in patients with metabolic-dysfunction associated compensated advanced chronic liver disease.

17. Transjugular intra-hepatic portosystemic shunt (TIPS) in elderly patients: preliminary analysis of a multicenter retrospective cohort.

20. First and further liver decompensation in patients with metabolic-dysfunction associated steatotic liver disease: what clinical impact?

21. Underdilation strategy for TIPS placement reduces incidence of overt hepatic encephalopathy without affecting clinical efficacy and survival: results of a multicenter prospective Italian study

23. Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis

26. Assessment of sarcopenia improves the prediction of post-TIPS mortality in older adult patients with cirrhosis.

27. Predicting post-TIPS hepatic encephalopathy risk in patients with cirrhosis and refractory ascites: a proof-of-concept study using a 4D MRI perfusional model.

28. Long-term prospective study of development of hepatocellular carcinoma in compensated cirrhosis

29. Systemic inflammation is associated with hyperdynamic circulation and predicts acute-on-chronic liver failure

30. Consensus conference on TIPS management: Techniques, indications, contraindications

32. Transient Elastography and Ultrasonography: Optimal Evaluation of Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Concurrent with Nonalcoholic Fatty Liver Disease

33. Clinical presentation and etiological spectrum of idiopathic non-cirrhotic portal hypertension (INCPH): data from the Italian Registry

39. The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias

43. A New Catheter for Large Veins: A Better Way.

44. Reply

45. Transjugular Intrahepatic Portosystemic Shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: A real-life, case-control study

46. Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19

47. Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF)

48. Prevalence, predictors, and severity of lean nonalcoholic fatty liver disease in patients living with human immunodeficiency virus

49. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study

50. Consensus conference on TIPS management: Techniques, indications, contraindications

Catalog

Books, media, physical & digital resources